1787-05-9Relevant articles and documents
Synthesis of novel anthraquinones: Molecular structure, molecular chemical reactivity descriptors and interactions with DNA as antibiotic and anti-cancer drugs
Al-Otaibi, Jamelah S.,EL Gogary, Tarek M.
, p. 799 - 809 (2017)
Anthraquinones are well-known anticancer drugs. Anthraquinones anticancer drugs carry out their cytotoxic activities through their interaction with DNA, and inhibition of topoisomerase II activity. Anthraquinones (AQ5 and AQ5H) were synthesized and studied with 1,5-DAAQ by computational and experimental tools. The purpose of this study is to shade more light on mechanism of interaction between anthraquinone DNA affinic agents and different types of DNA. This study will lead to gain of information useful for drug design and development. Molecular structures were optimized using DFT B3LYP/6-31 + G(d). Depending on intramolecular hydrogen bonding interactions four conformers of AQ5 were detected within the range of about 42 kcal/mol. Molecular reactivity of the anthraquinone compounds was explored using global and condensed descriptors (electrophilicity and Fukui functions). NMR and UV–VIS electronic absorption spectra of anthraquinones/DNA were investigated at the physiological pH. The interaction of the anthraquinones (AQ5 and AQ5H) were studied with different DNA namely, calf thymus DNA, (Poly[dA].Poly[dT]) and (Poly[dG].Poly[dC]). UV–VIS electronic absorption spectral data were employed to measure the affinity constants of drug/DNA binding using Scatchard analysis. NMR study confirms qualitatively the drug/DNA interaction in terms of peak shift and broadening.
Synthesis and pharmaceuticals of novel bis-substituted anthraquinone derivatives
-
Page 8, (2008/06/13)
This invention relates to novel anthraquinone compounds useful in the treatment of allergic, inflammatory conditions, antioxidant, tumor condition, stem cell application, tissue engineering, applied in treating age-associate tissue degeneration, reverse organ failure in chronic high-turnover disease and therapeutic compositions containing such compounds. The compounds of the present invention are 1,4-, 1,5- and 1,8-difunctionalized anthraquinones or analogs thereof. According to the practice of the invention, there are provided bis-symmetrical substituted anthraquinone compounds according to formula I: wherein R1, R2, R3 and R4 present a straight, aminoalkylamino side chains or branched chain alkyl group having 1 to 6 carbons which may be substituted with one or more groups of R5, or R1, R2, R3 and R4 present phenyl or benzyl which may be substituted with one or two groups of R6; wherein R5 is selected from the group consisting of halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, and —OCH2CH2CH3; and wherein R6 is selected from the group consisting of a straight or branched chain alkyl group having 1 to 4 carbons, halogen, —RNH2, —RNH2R, —ROH, —NO2, —OCH3, —OCH2CH3, —OCH2CH2CH3, —CH2Br, —CH2Cl, —CH2OH, —C(CH3)3, —(CH2)20H, —(CH2)3OH, —(CH2)4OH, —CH2NH2, —(CH2)2NH2, —(CH2)3NH2, —(CH2)4NH2, —(CH2)5NH2, —CH2N(CH3)2, —(CH2)2N(CH3)2, —(CH2)2NH(CH2)2OH, —(CH2)3NH(CH2)2OH, —(CH2)2NHCH2OH, —(CH2)3NHCH2OH, —CH2CH(CH3)2, —CHCl2, —CH(CH3)Cl, —(CH2)2Cl, —(CH2)3Cl, —(CH2)3Br, —(CH2)4Br, and —(CH2)4Cl. Chart 1. Activation of hTERT promoter-driven SEAP expression by c-Myc. About 1×107 hTERT-BJ1 cells were transfected with 13.5 μg each of plasmid pSEAP or pPhTERT-SEAP and of plasmid pMT2T or pMT2T-cMyc by electroporation. After 24 h, viable cells were harvested, and reinoculated at a density of 3×105/mL, and the SEAP activity after 24 h at 37 □. The transfection efficiency of each experiment was determined by cotransfection with 1.5 μg of plasmid pCMVβ. The values were determined from three experiments. P0.05 is presented by an asterisk.
Synthesis of aminoanthraquinone derivatives and their in vitro evaluation as potential anti-cancer drugs
Katzhendler,Gean,Bar-Ad,Tashma,Ben-Shoshan,Ringel,Bachrach,Ramu
, p. 23 - 30 (2007/10/02)
-